All questions
Question 1
A 72-year-old man with decompensated heart failure requires diuretic therapy. He is treated with Drug A, which produces a maximal diuresis of 2 liters of urine per day. His physician switches him to Drug B. Drug B produces a maximal diuresis of 4 liters per day, which is a more desirable clinical outcome for this patient. The dose required to achieve 50% of the maximal effect is 20 mg for Drug A and 40 mg for Drug B.
Based on this information, which of the following statements correctly compares the pharmacodynamic properties of Drug B to Drug A?
- Drug B has higher potency and higher efficacy.
- Drug B has lower potency but higher efficacy. (correct answer)
- Drug B has higher potency but lower efficacy.
- Drug B has lower potency and lower efficacy.
Explanation: Efficacy refers to the maximum effect a drug can produce, regardless of the dose. Drug B produces a greater maximal diuresis (4 L) than Drug A (2 L), so it has higher efficacy. Potency refers to the amount of drug needed to produce a given effect (often measured by ED50). Drug B requires a higher dose (40 mg) to achieve 50% of its maximal effect compared to Drug A (20 mg), indicating it has lower potency. Therefore, Drug B has lower potency but higher efficacy than Drug A.
Question 2
A 28-year-old woman with opioid use disorder is started on buprenorphine as part of a medication-assisted treatment program. Buprenorphine binds to the μ-opioid receptor but produces a less pronounced effect than morphine. When administered to a patient currently taking morphine, buprenorphine can precipitate withdrawal symptoms.
The ability of buprenorphine to act as both a treatment and a potential precipitant of withdrawal is best explained by which of the following pharmacodynamic properties?
- Full agonist with low potency
- Competitive antagonist
- Partial agonist (correct answer)
- Irreversible antagonist
Explanation: Buprenorphine is a partial agonist at the μ-opioid receptor. This means it binds to the receptor and produces a submaximal response (lower efficacy than full agonists like morphine). This property provides relief from cravings and withdrawal without causing the same degree of euphoria and respiratory depression. However, because it has high affinity for the receptor, it can displace full agonists like morphine. When it displaces morphine, the overall receptor stimulation decreases, leading to a net reduction in effect and precipitating withdrawal symptoms.
Question 3
In a laboratory experiment, a researcher is studying a G-protein coupled receptor that exhibits a low level of constitutive activity in the absence of any ligand. When Drug X is added, receptor activity increases significantly. When Drug Y is added, it prevents Drug X from binding and has no effect on its own. When Drug Z is added, the basal activity of the receptor decreases below its normal constitutive level.
Which of the following terms best describes Drug Z?
- Agonist
- Antagonist
- Partial agonist
- Inverse agonist (correct answer)
Explanation: An inverse agonist binds to the same receptor as an agonist but elicits the opposite pharmacological response. In systems with constitutive (basal) activity, an inverse agonist reduces this activity below the baseline level. Drug X is an agonist, as it increases activity. Drug Y is a neutral antagonist, as it blocks the agonist but has no effect on its own. Drug Z is an inverse agonist because it reduces the receptor's activity below the constitutive level.
Question 4
A researcher studying the effects of a new synthetic catecholamine on cardiac myocytes observes that a maximal inotropic response is achieved when only 10% of the β1-adrenergic receptors are occupied by the drug. Further increases in the drug concentration do not increase the contractile response.
The presence of which of the following best explains this observation?
- Receptor downregulation
- Partial agonism
- Spare receptors (correct answer)
- Competitive antagonism
Explanation: This phenomenon describes the concept of spare receptors. A system has spare receptors when a maximal pharmacologic response can be elicited by an agonist at a concentration that does not occupy all available receptors. This indicates a high degree of coupling between receptor activation and downstream signaling pathways. This is common for hormones like insulin and for catecholamines acting on β-adrenergic receptors. Partial agonism would result in a submaximal response. Downregulation is a decrease in receptor number over time. Competitive antagonism would inhibit the response.
Question 5
A phase III clinical trial for a new oral hypoglycemic agent is conducted in 500 patients with type 2 diabetes. A quantal dose-response curve is generated by plotting the dose of the drug against the percentage of patients who achieve a target hemoglobin A1c of less than 7.0%. The results show that at a dose of 50 mg, 250 of the 500 patients achieve the target response.
The dose of 50 mg in this study represents which of the following pharmacodynamic parameters?
- LD50 (Median lethal dose)
- TD50 (Median toxic dose)
- ED50 (Median effective dose) (correct answer)
- Emax (Maximal efficacy)
Explanation: The median effective dose (ED50) is the dose at which 50% of individuals in a population exhibit a specified quantal (all-or-none) effect. In this trial, the specified effect is achieving a target HbA1c < 7.0%. Since 250 out of 500 patients (50%) achieved this effect at a dose of 50 mg, this dose represents the ED50. LD50 and TD50 refer to lethal and toxic doses, respectively. Emax refers to the maximal response, not a population-based dose.
Question 6
In a clinical trial comparing two new antihypertensive drugs, Drug X and Drug Y, both are found to produce the same maximal decrease in mean arterial pressure. However, the dose of Drug X required to produce 50% of the maximal effect (ED50) is 10 mg, while the ED50 for Drug Y is 50 mg.
Which of the following statements best describes the pharmacodynamic properties of Drug X compared to Drug Y?
- Drug X has greater efficacy.
- Drug X has greater potency. (correct answer)
- Drug X is a partial agonist.
- Drug X has a larger therapeutic index.
Explanation: Potency refers to the concentration or dose of a drug required to produce 50% of its maximal effect. Since Drug X has a lower ED50 (10 mg) compared to Drug Y (50 mg), it is more potent. Efficacy is the maximal effect a drug can produce. The passage states that both drugs produce the same maximal effect, so their efficacies are equal. There is not enough information to determine if Drug X is a partial agonist or to compare their therapeutic indices.
Question 7
A 62-year-old man with stable angina and hypertension is treated with metoprolol, a competitive β1-adrenergic antagonist. He develops an allergic reaction and experiences bronchospasm. He is given epinephrine, a non-selective adrenergic agonist. A higher than usual dose of epinephrine is needed to achieve adequate bronchodilation via its β2-agonist effects.
How does the presence of metoprolol alter the dose-response curve for epinephrine at β-adrenergic receptors?
- Shifts the curve to the right, with no change in maximal effect. (correct answer)
- Shifts the curve to the left, with no change in maximal effect.
- Does not shift the curve, but decreases the maximal effect.
- Shifts the curve to the right and decreases the maximal effect.
Explanation: Metoprolol is a competitive antagonist. Competitive antagonists bind reversibly to the same site as the agonist (epinephrine). This increases the concentration of agonist required to produce a given effect, shifting the dose-response curve to the right (decreasing potency). However, because the binding is reversible, the antagonism can be overcome by adding more agonist. Therefore, the maximal effect (efficacy) is not changed. A noncompetitive antagonist would decrease the maximal effect.
Question 8
A pharmaceutical company is developing a new sedative. Preclinical studies in animals show that the median effective dose (ED50) for producing sedation is 20 mg/kg. The median toxic dose (TD50) that causes significant respiratory depression is 200 mg/kg.
Based on these data, what is the therapeutic index for this drug, and what does it suggest about the drug's safety profile?
- 0.1, suggesting a high margin of safety.
- 0.1, suggesting a low margin of safety.
- 10, suggesting a high margin of safety. (correct answer)
- 10, suggesting a low margin of safety.
Explanation: The therapeutic index (TI) is calculated as TD50 / ED50. In this case, TI = 200 mg/kg / 20 mg/kg = 10. A higher therapeutic index indicates a wider margin between the dose that produces a therapeutic effect and the dose that causes toxicity. Therefore, a TI of 10 suggests a relatively high (or wide) margin of safety, meaning that an overdose is less likely to occur with standard dosing adjustments compared to a drug with a TI of 2.
Question 9
A 34-year-old man with chronic back pain is managed with a high-dose oral morphine regimen. During a hospital admission for an unrelated issue, he is inadvertently administered nalbuphine, another opioid analgesic. Shortly after, he develops anxiety, yawning, lacrimation, and reports an increase in his back pain.
The precipitation of withdrawal symptoms in this patient is best explained by nalbuphine acting as what at the μ-opioid receptor?
- A full agonist with higher affinity than morphine
- A partial agonist/mixed agonist-antagonist (correct answer)
- A noncompetitive antagonist
- An inverse agonist
Explanation: Nalbuphine is a mixed agonist-antagonist opioid. It is an antagonist at μ-receptors and an agonist at κ-receptors. When given to a patient who is physically dependent on a full μ-agonist like morphine, nalbuphine competitively displaces morphine from the μ-receptors. Because nalbuphine has no agonist activity (or much lower intrinsic activity) at the μ-receptor, this displacement causes a rapid decrease in receptor stimulation, precipitating an acute withdrawal syndrome. This demonstrates that a partial agonist or antagonist can reverse the effects of a full agonist.
Question 10
A 40-year-old woman with Addison disease is prescribed hydrocortisone, a synthetic glucocorticoid. This hormone is essential for regulating metabolism and the immune response. After administration, the drug diffuses into target cells to exert its effect.
The receptor for hydrocortisone is located in which of the following cellular compartments?
- Cell membrane
- Cytoplasm (correct answer)
- Mitochondrial matrix
- Endoplasmic reticulum
Explanation: Steroid hormones, such as glucocorticoids (e.g., hydrocortisone), are lipophilic molecules that can easily cross the cell membrane. Their receptors are intracellular, located primarily in the cytoplasm. Upon binding the hormone, the receptor-hormone complex undergoes a conformational change, translocates to the nucleus, and acts as a transcription factor by binding to specific DNA sequences (glucocorticoid response elements) to modify gene expression.
Question 11
A 10-year-old boy with type 1 diabetes mellitus is taught how to administer subcutaneous injections of insulin. Insulin helps regulate blood glucose levels by promoting glucose uptake into skeletal muscle and fat cells. The binding of insulin to its receptor on the cell surface initiates this process.
The intracellular signaling cascade initiated by insulin binding to its receptor primarily involves which of the following mechanisms?
- Activation of a Gs protein and increased cAMP
- Autophosphorylation of tyrosine residues (correct answer)
- Opening of an ion channel
- Activation of a Gq protein and increased IP3
Explanation: The insulin receptor is a receptor tyrosine kinase. It consists of two α-subunits and two β-subunits. When insulin binds to the extracellular α-subunits, it causes a conformational change that activates the tyrosine kinase domain located on the intracellular portion of the β-subunits. This activation leads to autophosphorylation of tyrosine residues on the receptor itself, which then creates docking sites for other signaling proteins (like IRS), initiating downstream pathways that mediate insulin's metabolic effects.
Question 12
A 68-year-old man has been taking lorazepam for generalized anxiety disorder daily for the past 5 years. He tells his physician that while the initial dose of 1 mg was very effective, he now needs to take 3 mg to feel the same level of anxiety relief. He has not changed any other medications or habits.
The need for an increased dose to achieve the same effect, known as tolerance, is most likely due to which pharmacodynamic change at the GABAA receptor?
- Increased affinity of the receptor for benzodiazepines
- Changes in receptor conformation and coupling to chloride channels (correct answer)
- Upregulation of the number of GABAA receptors
- Increased synthesis of endogenous GABA
Explanation: Chronic use of benzodiazepines can lead to pharmacodynamic tolerance. This is thought to be caused by adaptive changes in the GABAA receptor itself. These changes include receptor downregulation (a decrease in the number of receptors) and, importantly, uncoupling of the benzodiazepine binding site from the GABA binding site and the chloride channel. This uncoupling means that even when the drug binds, it is less effective at potentiating the inhibitory effects of GABA, requiring a higher dose to achieve the same clinical effect.
Question 13
A patient is given Drug A, an agonist that produces a specific physiological response. When Drug B is co-administered, the maximal response that can be achieved by Drug A is reduced, even at very high concentrations of Drug A. Drug B has no effect when administered alone.
Which of the following terms best describes Drug B?
- Physiologic antagonist
- Competitive antagonist
- Partial agonist
- Noncompetitive antagonist (correct answer)
Explanation: A noncompetitive antagonist reduces the maximal effect (efficacy) of an agonist. This occurs because the antagonist binds to the receptor at a site different from the agonist (allosteric site) or binds irreversibly to the active site, effectively removing functional receptors from the system. Because this antagonism cannot be overcome by increasing the agonist concentration, the Emax is lowered. This is in contrast to a competitive antagonist, which would shift the dose-response curve to the right but not lower the Emax.
Question 14
A 19-year-old college student with asthma reports that he has been using his albuterol inhaler 10-12 times a day for the past week due to stress from final exams. He notes that the medication does not seem to relieve his wheezing as effectively as it used to. Albuterol is a short-acting β2-adrenergic agonist.
Which of the following pharmacodynamic changes is the most likely cause of the decreased effectiveness of albuterol in this patient?
- Upregulation of β2-adrenergic receptors
- Downregulation of β2-adrenergic receptors (correct answer)
- Increased drug metabolism
- Formation of antibodies against the drug
Explanation: The decreased effectiveness of albuterol with frequent use is a phenomenon known as tachyphylaxis. This rapid decrease in drug response is primarily caused by pharmacodynamic tolerance, specifically the downregulation of β2-adrenergic receptors on bronchial smooth muscle cells. Continuous or repeated exposure to an agonist leads to phosphorylation, internalization, and degradation of the receptors, reducing the number available to bind the drug and mediate a response. Upregulation would increase sensitivity. Increased metabolism is a pharmacokinetic change. Antibody formation is a rare immunologic reaction.
Question 15
A 58-year-old man with septic shock is given a continuous infusion of norepinephrine to increase his blood pressure. Norepinephrine primarily acts on α1-adrenergic receptors on vascular smooth muscle to cause vasoconstriction. Binding of norepinephrine to this receptor initiates a signal transduction cascade.
Activation of which of the following downstream signaling pathways is primarily responsible for the vasoconstrictive effect of norepinephrine?
- Activation of adenylyl cyclase and increased cAMP
- Activation of phospholipase C and increased intracellular calcium (correct answer)
- Opening of ligand-gated chloride channels
- Activation of receptor-associated tyrosine kinase
Explanation: α1-adrenergic receptors are G-protein coupled receptors that are linked to Gq proteins. Activation of the Gq protein stimulates phospholipase C (PLC). PLC then cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium from the sarcoplasmic reticulum, and DAG activates protein kinase C. The resulting increase in intracellular calcium leads to smooth muscle contraction and vasoconstriction.
Question 16
A 55-year-old woman has been taking propranolol, a non-selective beta-blocker, for the management of essential tremor for several years. She decides to abruptly stop her medication without consulting her physician. Two days later, she presents to the emergency department with palpitations, severe anxiety, and a heart rate of 130/min.
This patient's symptoms are most likely due to which of the following changes in her adrenergic receptors during long-term therapy?
- Receptor downregulation
- Receptor upregulation (correct answer)
- Decreased receptor affinity
- Formation of receptor autoantibodies
Explanation: Chronic blockade of receptors with an antagonist can lead to a compensatory increase in the number of receptors on the cell surface, a phenomenon known as upregulation. When the antagonist (propranolol) is abruptly withdrawn, the now-increased number of β-adrenergic receptors are exposed to endogenous catecholamines (epinephrine, norepinephrine), leading to an exaggerated or supersensitive response. This results in symptoms of sympathetic overactivity, such as tachycardia, palpitations, and anxiety.
Question 17
A 45-year-old woman with bipolar disorder is maintained on lithium therapy. Her physician informs her that she will require frequent blood tests to monitor the drug levels. The physician explains that this is because small changes in the drug's concentration can lead to either a loss of therapeutic effect or the development of serious toxicity, such as tremors, confusion, and renal dysfunction.
The need for close monitoring of this patient's medication is due to its narrow property of which of the following?
- Therapeutic index (correct answer)
- Bioavailability
- Volume of distribution
- Half-life
Explanation: The therapeutic index (TI) is a measure of a drug's safety, calculated as the ratio of the toxic dose (TD50) to the effective dose (ED50). A narrow TI, as seen with lithium, indicates that the dose required for therapeutic effect is very close to the dose that causes toxicity. This small margin of safety necessitates regular monitoring of plasma drug concentrations to ensure they remain within the therapeutic range and to prevent adverse effects.
Question 18
A 50-year-old farmer is brought to the emergency department with diaphoresis, urination, miosis, bronchospasm, and muscle weakness. He was recently exposed to an organophosphate pesticide. Organophosphates act by forming a stable, covalent bond with the active site of acetylcholinesterase, rendering the enzyme nonfunctional.
How would this exposure affect the dose-response relationship for acetylcholine at muscarinic receptors?
- Shift the curve to the right, decreasing potency
- Shift the curve to the left, increasing potency (correct answer)
- Decrease the maximal effect (Emax)
- Increase the maximal effect (Emax)
Explanation: Organophosphates are acetylcholinesterase inhibitors. By inhibiting the enzyme that breaks down acetylcholine (ACh), they increase the concentration and duration of action of ACh in the synaptic cleft. This effectively increases the amount of agonist available to bind to muscarinic and nicotinic receptors for any given level of neuronal release. An increased agonist concentration produces a greater effect at a lower stimulus level, which is represented by a leftward shift in the dose-response curve, indicating an increase in the apparent potency of acetylcholine.
Question 19
A 12-year-old girl with exercise-induced asthma is prescribed an albuterol inhaler. Albuterol is a selective β2-adrenergic agonist. When she uses the inhaler before exercise, it effectively prevents bronchoconstriction. The therapeutic effect of albuterol is mediated by the relaxation of bronchial smooth muscle.
The binding of albuterol to its receptor leads to smooth muscle relaxation through the increased intracellular concentration of which of the following second messengers?
- Inositol trisphosphate (IP3)
- Diacylglycerol (DAG)
- Cyclic adenosine monophosphate (cAMP) (correct answer)
- Cyclic guanosine monophosphate (cGMP)
Explanation: β2-adrenergic receptors are G-protein coupled receptors linked to Gs proteins. When an agonist like albuterol binds, the Gs protein activates adenylyl cyclase. Adenylyl cyclase then converts ATP to cyclic adenosine monophosphate (cAMP). Increased levels of cAMP in bronchial smooth muscle cells activate protein kinase A, which leads to phosphorylation of various proteins, resulting in decreased intracellular calcium and smooth muscle relaxation (bronchodilation).